Mersacidin, a new antibiotic from Bacillus Fermentation, isolation, purification and chemical characterization.

Chatterjee, Sukumar; Chatterjee, S. K.; Lad, Shashikant J.; Phansalkar, Mahesh S.; Rupp, Richard H.; Ganguli, B. N.; Fehlhaber, H.‐W.; Kogler, Herbert

doi:10.7164/antibiotics.45.832

Cited by 135 publications

(87 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…31 This class B peptide comprises three melan rings along with a dehydroalanine and an aminovinylmethylcysteine residue. Mersacidin has shown very promising activity against methicillin-resistant S. aureus.…”

Section: Mersacidin Is a Small Globular Lantibiotic That Is Produced Bymentioning

confidence: 99%

Fundamental functionality: recent developments in understanding the structure–activity relationships of lantibiotic peptides

Ross

Vederas

2010

J Antibiot

View full text Add to dashboard Cite

There has been great interest in the development of extremely potent antibacterial lantibiotic peptides for medicinal use and in food preservation. Of central importance to this endeavor is a strong understanding of which parts of the peptides are required for activity and which parts are expendable. Nisin, lacticin 481, nukacin ISK-1, mersacidin, lacticin 3147 and haloduracin represent many different types of lantibiotic peptides. In recent years, considerable advances toward understanding the structure-activity relationship of each of these lantibiotic systems have been achieved. This review will focus on the individual systems and the valuable information obtained from the many mutants produced.

show abstract

Section: Mersacidin Is a Small Globular Lantibiotic That Is Produced Bymentioning

confidence: 99%

Fundamental functionality: recent developments in understanding the structure–activity relationships of lantibiotic peptides

Ross

Vederas

2010

J Antibiot

View full text Add to dashboard Cite

show abstract

“…The Listeria isolates used as indicator strains are listed in Table 1. Luria-Bertani (LB), brainheart (BH) and PALCAM media were of commercial origin (Becton-Dickinson, Le Pont de Chaix, France), whereas CAT medium composition was as described elsewhere [6]. Genomic DNA was purified using the Wizard genomic purification kit (Promega).…”

Section: Strains Media and General Genetic Techniquesmentioning

confidence: 99%

Antilisterial Activity on Poultry Meat of Amylolysin, a Bacteriocin from Bacillus amyloliquefaciens GA1

Halimi

Dortu

Arias

et al. 2010

Probiotics & Antimicro. Prot.

View full text Add to dashboard Cite

This paper describes the production, the purification and the antilisterial activity of amylolysin, a novel bacteriocin from B. amyloliquefaciens GA1. The strain genome was first analysed using PCR techniques for the presence of gene clusters that direct the synthesis of characterised bacteriocins from B. amyloliquefaciens and the closely related B. subtilis. Our results suggest that amylolysin corresponds to a novel bacteriocin. The effect of amylolysin on the growth of different isolates of Listeria monocytogenes was evaluated in poultry meat during 21 days of storage at 4°C. A potent antilisterial effect was observed for all the indicator strains tested, demonstrating that amylolysin is a novel bacteriocin that could be used as a food preservative.

show abstract

“…Additionally, the unusual amino acid ␣,␤-didehydroalanine is found. Mersacidin carries no net charge and has overall hydrophobic properties (5). It is produced by Bacillus sp.…”

mentioning

confidence: 99%

Mode of action of the lantibiotic mersacidin: inhibition of peptidoglycan biosynthesis via a novel mechanism?

Brötz

Bierbaum

Markus

et al. 1995

Antimicrob Agents Chemother

129

View full text Add to dashboard Cite

Mersacidin is an antibiotic peptide produced byThe term lantibiotics designates a group of lanthionine (and/or 3-methyllanthionine)-containing peptides with antibiotic activity against gram-positive bacteria (25). In contrast to peptide antibiotics like bacitracin or gramicidin S (10), lantibiotics are ribosomally synthesized and show unique structural properties, which arise from posttranslational modifications (for reviews, see references 3 and 9).With a molecular mass of 1,825 Da, mersacidin is the smallest lantibiotic known so far. Its propeptide template consists of 20 amino acids, 8 of which are modified to yield 4 thioether amino acids: 3 3-methyllanthionines and 1 2-aminovinyl-2-methylcysteine. This leads to the formation of four intramolecular heterocyclic rings. Additionally, the unusual amino acid ␣,␤-didehydroalanine is found. Mersacidin carries no net charge and has overall hydrophobic properties (5). It is produced by Bacillus sp. strain HIL Y-85,54728 and is active against several gram-positive bacteria such as streptococci, bacilli, and staphylococci including methicillin-resistant Staphylococcus aureus strains; enterococci are relatively insusceptible (4, 14). Although in vitro mersacidin is less active than vancomycin, teicoplanin, and daptomycin (17), its activity in vivo is at least comparable to that of vancomycin in the treatment of experimental staphylococcal infections (including those caused by methicillin-resistant S. aureus strains) in mice (4,14).In addition to its potential therapeutical value, mersacidin has been the subject of increased interest because of its position among the lantibiotics described so far, which have been classified into two groups (9). The type A lantibiotics (e.g., Pep5 and nisin) are screw-shaped, positively charged, amphipathic molecules which exert their primary bactericidal action by the formation of pores in the cytoplasmic membrane (20). The type B lantibiotics, as defined so far (e.g., duramycin and cinnamycin), possess a globular shape, carry no net charge or a negative charge, and are described as inhibitors of phospholipase A 2 or the angiotensin-converting enzyme (3). Mersacidin does not completely conform to either group because of atypical structural features (9, 11).Here, we report that it is also different regarding its mode of bactericidal activity. We show that mersacidin inhibits peptidoglycan biosynthesis, probably on the level of transglycosylation. Furthermore, we demonstrate that on the molecular level its mode of action differs from those of glycopeptide antibiotics like vancomycin or teicoplanin. This opens the possibility of using a new target for the antibiotic treatment of methicillinresistant S. aureus strains and makes mersacidin an interesting tool for the investigation of peptidoglycan biosynthesis of gram-positive bacteria. MATERIALS AND METHODSBacterial strains and growth conditions. Staphylococcus simulans 22 (formerly Staphylococcus cohnii 22; Institute for Medical Microbiology and Immunology of the University of Bonn, Bonn, ...

show abstract

Mersacidin, a new antibiotic from Bacillus Fermentation, isolation, purification and chemical characterization.

Cited by 135 publications

References 1 publication

Fundamental functionality: recent developments in understanding the structure–activity relationships of lantibiotic peptides

Fundamental functionality: recent developments in understanding the structure–activity relationships of lantibiotic peptides

Antilisterial Activity on Poultry Meat of Amylolysin, a Bacteriocin from Bacillus amyloliquefaciens GA1

Mode of action of the lantibiotic mersacidin: inhibition of peptidoglycan biosynthesis via a novel mechanism?

Contact Info

Product

Resources

About